• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Abpro Holdings Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    4/16/25 4:10:08 PM ET
    $ABP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABP alert in real time by email
    false 0001893219 0001893219 2025-04-10 2025-04-10 0001893219 ABP:SharesOfCommonStockParValue0.0001PerShareMember 2025-04-10 2025-04-10 0001893219 ABP:WarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf11.50Member 2025-04-10 2025-04-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): April 10, 2025

     

    Abpro Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41224   87-1013956
    (State or other jurisdiction
    of incorporation)
      (Commission File Number)  

    (I.R.S. Employer

    Identification No.)

     

    68 Cummings Park Drive
    Woburn, MA

      01801
    (Address of principal executive offices)   (Zip Code)

     

    1-800-396-5890

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol(s)   Name of Each Exchange on Which Registered
    Shares of Common Stock, par value $0.0001 per share   ABP   The Nasdaq Stock Market LLC
    Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50   ABPWW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

     

      Item 3.01 Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing.

     

    On April 10, 2025, Abpro Holdings, Inc. (the “Company”) received two letters from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”). One letter (the “MVPHS Notice”) indicated that based upon Nasdaq’s review of the Company’s Market Value of Publicly Held Shares (“MVPHS”) for the last 30 consecutive business days prior to the date of the MVPHS Notice, the Company no longer meets the requirements of Nasdaq Listing Rule 5450(b)(2)(C), which requires listed securities to maintain a minimum MVPHS of $15,000,000 (the “MVPHS Requirement”). The Company intends to monitor the market value of the Company’s listed securities and may, if appropriate, consider available options to regain compliance with the MVPHS Requirement.

     

    Under Nasdaq Listing Rule 5810(c)(3)(D), the Company has a period of 180 calendar days (or until October 7, 2025) to regain compliance with the MVPHS Requirement. If at any time during this compliance period the Company’s MVPHS closes at $15,000,000 or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance with the rule prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Nasdaq hearing’s panel.

     

    The Company is working diligently to regain compliance with Nasdaq’s listing rules. This notification has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. 

     

    The Company also received a letter from the Staff (the “MVLS Deficiency Notice”) notifying the Company that from February 20, 2025, to April 9, 2025, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”). An indicator will be displayed with quotation information related to the Company’s securities on NASDAQ.com and NASDAQTrader.com and may be displayed by other third-party providers of market data information, however, the Notice does not impact the listing of the Company’s securities on The Nasdaq Global Market at this time.

     

    The MVLS Deficiency Notice has no immediate effect on the listing of the Company’s common stock, and the Company’s common stock continues to trade on the Nasdaq Global Market under the symbol “ABP.”

     

    In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has 180 calendar days from the date of the MVLS Deficiency Notice, or until October 7, 2025 (the “Compliance Date”), to regain compliance with respect to the MVLS Requirement. The MVLS Deficiency Notice states that to regain compliance with the MVLS Requirement, the Company’s MVLS must close at $50 million or more for a minimum of ten consecutive business days during the compliance period ending on the Compliance Date.

     

    1

     

     

    If the Company does not regain compliance by the Compliance Date, Nasdaq will provide written notice to the Company that its securities are subject to delisting. At that time, the Company may appeal any such delisting determination. However, there can be no assurance that, if the Company receives a delisting notice from the Staff and appeals the delisting determination, such appeal would be successful. Alternatively, the Company may consider applying for transfer to The Nasdaq Capital Market (the “Capital Market”).

     

    The Company intends to actively monitor the Company’s MVLS between now and the Compliance Date and will take all reasonable measures available to the Company to regain compliance with the MVLS Requirement. While the Company is exercising diligent efforts to maintain the listing of its common stock on Nasdaq, there can be no assurance that the Company will be able to regain or maintain compliance with the applicable continued listing standards set forth in the Nasdaq Listing Rules.

     

    Cautionary Statement Regarding Forward-Looking Statements

     

    This Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to: statements regarding the Company’s ability to regain compliance with the MVPHS Requirement and the MVLS Requirement; the Company’s intent to monitor its MVPHS and MVLS and take all reasonable measures available to the Company for continued listing on The Nasdaq Global Market; and the Company’s success in appealing any delisting determination.

     

    In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to, the Company’s ability to regain compliance with the MVPHS Requirement and the MVLS Requirement; and the other important factors outlined under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on April 15, 2025, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC’s website at www.sec.gov. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this Current Report on Form 8-K to reflect changes since the date of this Current Report on Form 8-K, except as may be required by law.

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      ABPRO HOLDINGS, INC.
         
      By: /s/ Miles Suk
      Name:  Miles Suk
      Title: Chief Executive Officer
         
    Dated: April 16, 2025    

     

     

    3

     

     

    Get the next $ABP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ABP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman Suk Jin Wook (Miles) bought $4,212 worth of shares (16,200 units at $0.26), increasing direct ownership by 12% to 146,477 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      5/19/25 8:37:52 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Suk Jin Wook (Miles) bought $1,081 worth of shares (4,325 units at $0.25), increasing direct ownership by 3% to 130,277 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      5/1/25 4:21:30 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Suk Jin Wook (Miles) bought $11,113 worth of shares (34,002 units at $0.33), increasing direct ownership by 37% to 125,902 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      4/25/25 4:58:51 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABP
    SEC Filings

    See more
    • SEC Form 424B3 filed by Abpro Holdings Inc

      424B3 - Abpro Holdings, Inc. (0001893219) (Filer)

      5/15/25 5:25:47 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Abpro Holdings Inc

      10-Q - Abpro Holdings, Inc. (0001893219) (Filer)

      5/15/25 4:49:25 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Abpro Holdings Inc

      EFFECT - Abpro Holdings, Inc. (0001893219) (Filer)

      5/6/25 12:15:38 AM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman Suk Jin Wook (Miles) bought $4,212 worth of shares (16,200 units at $0.26), increasing direct ownership by 12% to 146,477 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      5/19/25 8:37:52 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Suk Jin Wook (Miles) bought $1,081 worth of shares (4,325 units at $0.25), increasing direct ownership by 3% to 130,277 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      5/1/25 4:21:30 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and Chairman Suk Jin Wook (Miles) bought $11,113 worth of shares (34,002 units at $0.33), increasing direct ownership by 37% to 125,902 units (SEC Form 4)

      4 - Abpro Holdings, Inc. (0001893219) (Issuer)

      4/25/25 4:58:51 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

      Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profileAbpro and Celltrion have a strategic partnership for worldwide development and commercialization of ABP-102/CT-P72HER2-positive cancers represent up to 30 percent of all cases of breast, gastric, pancreatic, colorectal and other forms of cancer WOBURN, Mass., April 27, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, and Celltrion, a leading biopharmaceutical company, today unveiled preclinical data for ABP-102/CT-P72 in an oral presentation at the

      4/27/25 2:00:00 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025

      WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases, today announced an oral presentation of preclinical data for ABP-102/CT-P72 at the American Association for Cancer ResearchⓇ Annual Meeting 2025 ("AACR 2025") in the New Drugs on the Horizon session. AACR 2025 is taking place April 25-30, at the McCormick Place Convention Center in Chicago. Invited speaker presentation details Title:ABP-102/CT-P72: a novel HER2 x CD3 T cell engager with selective activity for HER2-overexpressing tumors and reduced activity on cells with

      3/25/25 4:30:18 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Abpro Statement on the Departure of Former CEO Ian Chan

      WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, "As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his service and wish him well. This leadership transition, however, does not affect our stability or direction. Instead, it marks the first step toward a stronger, more promising future. We remain fully co

      3/10/25 6:34:55 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABP
    Leadership Updates

    Live Leadership Updates

    See more
    • Abpro Statement on the Departure of Former CEO Ian Chan

      WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (NASDAQ:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan. Commenting on the leadership change, Abpro Board Chairman and CEO Miles Suk, said, "As disclosed in our regulatory filing on Friday, the Board has decided to part ways with Ian Chan. I want to thank Ian for his service and wish him well. This leadership transition, however, does not affect our stability or direction. Instead, it marks the first step toward a stronger, more promising future. We remain fully co

      3/10/25 6:34:55 PM ET
      $ABP
      Biotechnology: Pharmaceutical Preparations
      Health Care